Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis.
NCT07600021 is registered in ClinicalTrials.gov with InnovStone Therapeutics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis.
- Lead sponsor
- InnovStone Therapeutics Limited
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- December 30, 2027
- Enrollment
- 156 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.